Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
399.80
-20.00 (-4.76%)
At close: Aug 7, 2025, 4:00 PM HKT
-4.76%
Market Cap91.37B
Revenue (ttm)2.06B
Net Income (ttm)-283.88M
Shares Out228.54M
EPS (ttm)-1.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume937,880
Average Volume798,740
Open424.00
Previous Close419.80
Day's Range398.80 - 426.20
52-Week Range148.00 - 436.40
Beta0.80
RSI56.05
Earnings DateAug 19, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,837
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6990
Full Company Profile

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.